The Accelerating Medicines Partnership is a public-private collaboration among the National Institutes of Health, pharmaceutical companies, and non-profit organizations.
The goal of the work is to pinpoint the genes, proteins, and cell signaling pathways involved in disease pathogenesis and response to current therapies, and to identify tissue specific targets for new therapies. Network researchers are employing emerging single cell technologies, big data tools, and invaluable samples obtained from consenting rheumatoid arthritis (RA) patients or lupus patients. All results from this partnership will be made available to medical researchers and to the public.
Main Areas of Focus
- To better understand the underlying disease process and identify parts of the immune system that aren't functioning correctly in people with RA and lupus
- To find targeted, effective therapies for RA and lupus through the analysis of genes, proteins, chemical pathways, and networks involved at a single cell level